RTP Mobile Logo
RTP TV: Part IV — Advanced Prostate Cancer
Released October 2012

The fourth seminar of our online, integrated educational course explores topics relevant to the treatment of advanced prostate cancer. Originally held on October 11, 2012, Part IV features Drs Christopher J Logothetis and A Oliver Sartor.

CE Disclosures and Faculty Information


    This activity is intended for medical oncologists, radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer.


    Prostate cancer is the most frequently diagnosed cancer in men, with an estimated 241,740 new cases every year in the United States. While virtually all locally advanced or metastatic sites of tumor are initially reliant on androgen stimulation for growth and respond to treatment with androgen deprivation therapy, inevitably resistance to hormone blockade eventually develops, culminating in the recurrence of highly aggressive castration-resistant prostate cancer (CRPC). Recently published randomized controlled studies focused specifically on this population have led to the emergence of novel therapeutic strategies for patients with CRPC and resulted in a paradigm shift to the multidisciplinary care of this disease. A number of pivotal data sets illustrating the benefits of several novel agents indicate that additional therapeutic options may soon be available that will warrant consideration and integration into prostate cancer care. The treatment landscape and available options for prostate cancer have thus broadened, making choices more challenging for many healthcare professionals and patients, and a once stagnant systemic treatment algorithm, largely confined to medical or surgical castration, has evolved into delivery of cutting edge antineoplastic therapy necessitating learning opportunities for urologists and medical oncologists.

    • Discern the clinically relevant differences between androgen-insensitive and castration-resistant metastatic prostate cancer (PC) to guide the integration of secondary hormonal agents into current treatment algorithms.
    • Recall existing and emerging research demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-pretreated castration-resistant PC, and use this information to guide treatment planning for these patients.
    • Efficiently identify patients with skeletal metastases and educate them regarding the known efficacy and safety data related to radium-223 chloride.
    • Employ interactive learning to effectively apply evidence-based research findings in the determination of best-practice sequencing of available systemic agents for patients with metastatic PC.
    • Explore the emerging data and active research evaluating novel agents in the setting of advanced PC, and discuss the biologic basis for their clinical activity.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 75% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/RTPTV2012/Archives/4/CME.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Christopher J Logothetis, MD
    Chairman/Professor, Genitourinary Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Paid Research: Dendreon Corporation, Johnson & Johnson Pharmaceuticals.

    A Oliver Sartor, MD

    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Sanofi; Clinical Investigator: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Algeta ASA, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Medivation, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi, Teva.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals and Millennium: The Takeda Oncology Company.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2012
    Expiration date: October 2013

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):